Scarica l'app Stockscreener
3.06
0.49%
0.015
Dopo l'orario di chiusura:
3.07
0.010
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Anixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Anixa Hikes on Tests - Baystreet.ca
Anixa Biosciences Advances Ovarian Cancer CAR-T Trial with 10x Dose Increase | ANIX Stock News - StockTitan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in October - Defense World
Anixa Biosciences, Inc. (NASDAQ:ANIX) Sees Large Decrease in Short Interest - MarketBeat
Anixa Biosciences Inc. (ANIX) Quarterly 10-Q Report - Quartzy
Anixa reports progress in breast cancer vaccine trial - Investing.com
Anixa reports progress in breast cancer vaccine trial By Investing.com - Investing.com Canada
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
Anixa Biosciences Reports Promising Phase 1 Vaccine Results - TipRanks
Anixa Biosciences to Present Phase 1 Breast Cancer Vaccine Trial Data at SITC Meeting | ANIX Stock News - StockTitan
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
ANIXA BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 - StockTitan
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting - PR Newswire
US Penny Stocks To Consider In October 2024 - Simply Wall St
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial - Yahoo Finance
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Drops By 8.9% - MarketBeat
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development - BioSpace
Anixa Biosciences Seeks Protocol Change to Enable Repeat Dosing in Trial for Ovarian Cancer CER-T - CGTLive™
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial By Investing.com - Investing.com South Africa
Anixa seeks approval for repeat CAR-T doses in ovarian cancer trial - Investing.com
California Biotech's Target Price 200% Higher Than Current - Streetwise Reports
ANIXAnixa Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial - StockTitan
Anixa announces plans to launch Phase II breast cancer vaccine trial - Clinical Trials Arena
Anixa Shares Rise on Plans for Phase 2 Study of Breast Cancer Vaccine - MarketWatch
Anixa Biosciences sets Phase 2 trial for breast cancer vaccine - Investing.com
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine - PR Newswire
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
FY2024 EPS Estimates for Anixa Biosciences, Inc. (NASDAQ:ANIX) Lifted by Analyst - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference - PR Newswire
HC Wainwright Reaffirms Buy Rating for Anixa Biosciences (NASDAQ:ANIX) - MarketBeat
Why researchers hope a new vaccine will help in the fight against breast cancer - FOX 13 News Utah
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate - Simply Wall St
Anixa Biosciences (NASDAQ:ANIX) Announces Earnings Results - MarketBeat
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium - StockTitan
Nations Financial Group Inc. IA ADV Has $50,000 Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Anixa Biosciences to Present at Biotech Showcase 2024 - GuruFocus.com
Anixa Biosciences (FRA:CY71) Earnings per Share (Diluted) : €-0.34 (TTM As of Apr. 2024) - GuruFocus.com
ANIX (Anixa Biosciences) GF Value Rank : 0 (As of Aug. 16, 2024) - GuruFocus.com
Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Grows By 33.0% - MarketBeat
Anixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Update - Defense World
Virtu Financial LLC Has $50,000 Stake in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Stock Rating Upgraded by EF Hutton Acquisition Co. I - MarketBeat
Anixa Biosciences (NASDAQ:ANIX) Upgraded to “Strong-Buy” at EF Hutton Acquisition Co. I - Defense World
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Purchases 21,646 Shares of Stock - Defense World
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):